和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02256 和誉-B

休市中 04-30 16:08:13

12.920

-0.300

-2.27%

最高13.290	最低12.880	成交量217.30万
今开13.220	昨收13.220	日振幅3.10%
总市值87.08亿	流通市值87.08亿	总股本6.74亿
成交额2,825万	换手率0.32%	流通股本6.74亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02256","market":"HK","secType":"STK","nameCN":"和誉-B","latestPrice":12.92,"timestamp":1777536493005,"preClose":13.22,"halted":0,"volume":2173000,"delay":0,"changeRate":-0.022692889561270854,"floatShares":674000000,"shares":674000000,"eps":0.088442,"marketStatus":"休市中","change":-0.3,"latestTime":"04-30 16:08:13","open":13.22,"high":13.29,"low":12.88,"amount":28246349,"amplitude":0.031014,"askPrice":12.99,"askSize":1000,"bidPrice":12.92,"bidSize":19000,"shortable":3,"etf":0,"ttmEps":0.085,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777858200000},"marketStatusCode":7,"adr":0,"listingDate":1634054400000,"exchange":"SEHK","adjPreClose":13.22,"openAndCloseTimeList":[[1777512600000,1777521600000],[1777525200000,1777536000000]],"volumeRatio":1.1118501842793997,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02256/wiki","defaultTab":"wiki","newsList":[{"id":"2630408304","title":"和誉-B(02256.HK)完成配售4290万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2630408304","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630408304?lang=zh_cn&edition=full","pubTime":"2026-04-28 20:27","pubTimestamp":1777379222,"startTime":"0","endTime":"0","summary":"格隆汇4月28日丨和誉-B(02256.HK)公告，公司欣然宣布，配售已于2026年4月28日完成。合共4290万股新股份已按配售价每股股份12.18港元成功配售予不少于六(6)名承配人，据董事经作出一切合理查询后所知、所悉及所信，该等承配人连同彼等各自的最终实益拥有人均为独立第三方。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260428/32185159.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU2778985437.USD","IE00B5MMRT66.SGD","02256","LU2476274308.USD","IE00BPRC5H50.USD","LU2476274720.SGD","IE00B543WZ88.USD","LU2488822045.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100524554","title":"和誉-B配售4,290万股并披露股份回购进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1100524554","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100524554?lang=zh_cn&edition=full","pubTime":"2026-04-28 20:16","pubTimestamp":1777378581,"startTime":"0","endTime":"0","summary":"和誉开曼有限责任公司于2026年4月28日发布公告。根据公告，因公司于2026年4月21日签订的配售协议并在当日及同年4月28日的公告中披露相关详情，配售新发行42,900,000股股份，占此次发行前公司已发行股份约6.37%，每股发行价为12.18港元。发行完成后，公司已发行股份总数增至716,461,350股，库存股份仍为7,744,000股，合计724,205,350股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"和誉-B配售4,290万股并披露股份回购进展","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105966957","title":"和誉-B授予董事股份购回授权，规模达已发行股本一成","url":"https://stock-news.laohu8.com/highlight/detail?id=1105966957","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105966957?lang=zh_cn&edition=full","pubTime":"2026-04-28 20:01","pubTimestamp":1777377688,"startTime":"0","endTime":"0","summary":"和誉开曼有限责任公司宣布，董事会已获股东周年大会授予一般授权，可在指定期间内按不超过公司已发行股本总数10%的规模进行股份购回。根据第七项普通决议案，董事会获准在未来一段“有关期间”内，于香港联交所或其他获认可证券交易所购回股份。若行使该授权，公司将严格遵守开曼群岛法律以及联交所相关规则。董事会强调，实施购回决策前会进行充分评估，并兼顾公司长远经营需求，表示上述授权及措施符合公司及股东的整体最佳利益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"和誉-B授予董事股份购回授权，规模达已发行股本一成","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103038898","title":"和誉-B2025年度业绩稳健增长 多款创新药物取得进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1103038898","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103038898?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:55","pubTimestamp":1777377340,"startTime":"0","endTime":"0","summary":"和誉-B由Abbisko Cayman Limited注册成立于开曼群岛，现于香港联合交易所有限公司上市，主要在上海及香港设有运营基地。公司核心团队于2016年4月共同创立，现总部及中国主要办公地点位于上海浦东新区张江高科技园区，经营范围覆盖创新生物制剂及基因治疗技术的研发和商业化应用。整体而言，和誉-B在2025年取得了收入与净利润的同步较快增长，巩固了其在创新药研发与商业化方面的核心竞争力。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"和誉-B2025年度业绩稳健增长 多款创新药物取得进展","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630935581","title":"港股异动 | 和誉-B(02256)盘中涨超6% 于2026年AACR年会展示包含pan-KRAS等六项研究进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2630935581","media":"智通财经","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630935581?lang=zh_cn&edition=full","pubTime":"2026-04-27 10:27","pubTimestamp":1777256822,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和誉-B盘中涨超6%，截至发稿，涨6.62%，报14.5港元，成交额1348.34万港元。消息面上，和誉-B发布公告，公司在4月17日至22日于美国圣地亚哥举行的美国癌症研究协会2026年年会上，以壁报形式展示了六项最新临床前研究及转化医学研究成果。研究结果表明，ABSK211可通过多机制协同显著增强抗肿瘤效果，为后续联合多种治疗策略进入临床开发提供了支持。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434199.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2778985437.USD","BK4585","IE00B5MMRT66.SGD","02256","LU2476274308.USD","IE00BPRC5H50.USD","LU2476274720.SGD","IE00B543WZ88.USD","VXUS","BK4588","LU2488822045.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629810094","title":"和誉-B(02256)：加速创新价值释放，超5亿港元配售叠加GIC举牌释放长投信号","url":"https://stock-news.laohu8.com/highlight/detail?id=2629810094","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629810094?lang=zh_cn&edition=full","pubTime":"2026-04-24 18:38","pubTimestamp":1777027110,"startTime":"0","endTime":"0","summary":"作为一家手握两款重磅“十亿美元分子”和多款具备FIC/BIC潜力创新管线品种的先锋药企，和誉-B在创新研发和BD交易的加持下，已连续两年实现年度盈利。此次GIC以每股均价12.18港元买入和誉约3800万股普通股股份，价值约4.6亿港元。目前GIC最新持股数目为3800万股股份，持仓比例升至5.25%。据悉，GIC是新加坡最大的国际投资机构，以长线价投风格著称。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02256","LU2476274308.USD","LU2488822045.USD","LU2476274720.SGD","LU2778985437.USD","GIC","IE00B5MMRT66.SGD","IE00B543WZ88.USD","BK1161","IE00BPRC5H50.USD","BK4104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629315074","title":"和誉-B(02256)：和誉医药于2026年AACR年会展示六项研究进展，聚焦pan-KRAS、四代EGFR及合成致死等创新路线","url":"https://stock-news.laohu8.com/highlight/detail?id=2629315074","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629315074?lang=zh_cn&edition=full","pubTime":"2026-04-23 08:05","pubTimestamp":1776902727,"startTime":"0","endTime":"0","summary":"研究结果表明，ABSK211可通过多机制协同显著增强抗肿瘤效果，为后续联合多种治疗策略进入临床开发提供了支持。研究结果支持进一步开发ABK-EGFR-1作为下一代靶向治疗药物，用于 EGFR耐药肿瘤，尤其适用于伴有脑转移的患者。和誉医药在本次2026年AACR年会上集中展示了多个产品管线的最新临床前研究和转化医学研究进展，体现了公司在早期药物发现与开发方面的强大能力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432385.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2476274308.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU2778985437.USD","LU2476274720.SGD","159938","IE00BPRC5H50.USD","LU2488822045.USD","09939","BK1515","BK1574","BK1161","02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629809482","title":"和誉-B午后涨超4% 公司拟配股净筹超5亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629809482","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629809482?lang=zh_cn&edition=full","pubTime":"2026-04-22 13:44","pubTimestamp":1776836673,"startTime":"0","endTime":"0","summary":"4月22日，和誉-B(02256.HK)午后涨超4%，截至发稿涨4.36%，报14.36港元，成交额1883.42万港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604223713881895.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604223713881895.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","LU2778985437.USD","IE00B5MMRT66.SGD","LU2476274308.USD","LU2488822045.USD","02256","IE00BPRC5H50.USD","IE00B543WZ88.USD","LU2476274720.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629086377","title":"和誉-B(02256)折让约8.35%配股 净筹约5.17亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629086377","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629086377?lang=zh_cn&edition=full","pubTime":"2026-04-21 08:58","pubTimestamp":1776733126,"startTime":"0","endTime":"0","summary":"金吾财讯 | 和誉-B(02256)公告公布，拟配售4290万股股份，占经配售股份发行扩大的已发行股份总数的5.99%。每股配售价12.18港元，较上交易日收市价13.29港元折让约8.35%。配售事项集资所得款项总额约为5.23亿港元，净额约5.17亿港元，拟将其中约90%用于研发创新的肿瘤及非肿瘤候选药物、推进国际多中心临床试验及潜在的商业化活动；及约10%作一般及公司用途。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250110/YjkxOTY0MzQxMTgyOTU2MzA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/YjkxOTY0MzQxMTgyOTU2MzA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1979483","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BPRC5H50.USD","02256","LU2778985437.USD","LU2476274308.USD","IE00B543WZ88.USD","BK1161","LU2476274720.SGD","IE00B5MMRT66.SGD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629770410","title":"和誉-B(02256.HK)拟配售4290万股 净筹5.17亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629770410","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629770410?lang=zh_cn&edition=full","pubTime":"2026-04-21 08:47","pubTimestamp":1776732421,"startTime":"0","endTime":"0","summary":"格隆汇4月21日丨和誉-B发布公告，2026年4月21日，公司与配售代理(即花旗)订立配售协议，据此，配售代理同意作为公司的代理人，以尽力基准促使合共不少于六名承配人按配售协议所载条款及条件按配售价每股配售股份12.18港元购买4290万股配售股份。配售股份总数将为4290万股，占于本公告日期已发行股份总数的约6.37%。　　配售所得款项总额预计将合共约为5.225亿港元，而配售所得款项净额预计将合共约为5.173亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260421/32158951.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02256","BK1161","IE00B543WZ88.USD","LU2476274720.SGD","IE00BPRC5H50.USD","IE00B5MMRT66.SGD","LU2476274308.USD","LU2488822045.USD","LU2778985437.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629770535","title":"和誉-B(02256)拟按每股12.18港元配股 净筹约5.17亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629770535","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629770535?lang=zh_cn&edition=full","pubTime":"2026-04-21 08:33","pubTimestamp":1776731616,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B(02256)公布，于2026年4月21日，该公司拟透过配售代理发行4290万股配售股份，每股配售股份12.18港元，配售所得净额约5.17亿港元，约90%用于研发创新的肿瘤及非肿瘤候选药物、推进国际多中心临床试验及潜在的商业化活动;及约10%作一般及公司用途。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431056.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02256","IE00B5MMRT66.SGD","LU2778985437.USD","EWH","IE00BPRC5H50.USD","LU2488822045.USD","LU2476274308.USD","IE00B543WZ88.USD","BK1161","LU2476274720.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187116400","title":"和誉-B：此次配售预计募集资金总额约5.225亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1187116400","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187116400?lang=zh_cn&edition=full","pubTime":"2026-04-21 08:29","pubTimestamp":1776731351,"startTime":"0","endTime":"0","summary":"和誉开曼有限公司宣布，其近期进行的股份配售计划预计将筹集总额约为5.225亿港元的毛收益。此次融资活动旨在为公司未来的业务拓展和研发管线推进提供资金支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02256","LU2476274720.SGD","LU2488822045.USD","IE00B5MMRT66.SGD","LU2476274308.USD","IE00B543WZ88.USD","LU2778985437.USD","IE00BPRC5H50.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625942275","title":"和誉-B(02256)授出29万份购股权及29万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2625942275","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625942275?lang=zh_cn&edition=full","pubTime":"2026-04-08 21:49","pubTimestamp":1775656146,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B(02256)发布公告，公司于2026年4月8日根据首次公开发售后购股权计划授出29万份购股权予公司的3名雇员，惟须待购股权承授人接纳方可作实。公司于2026年4月8日根据2019年股权激励计划授出29万份受限制股份单位予公司的3名雇员，惟须待受限制股份单位承授人接纳方可作实。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426222.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","LU2476274720.SGD","LU2778985437.USD","02256","LU2476274308.USD","BK1161","IE00BPRC5H50.USD","IE00B543WZ88.USD","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138700288","title":"和誉-B更新3月股份变动月报表，已发行股份增加1,200,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1138700288","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138700288?lang=zh_cn&edition=full","pubTime":"2026-04-02 16:37","pubTimestamp":1775119053,"startTime":"0","endTime":"0","summary":"和誉开曼有限责任公司于2026年4月2日发布2026年3月股份变动月报表。报告显示，截至2026年3月31日，公司法定股本维持5,000,000,000股普通股，面值为每股0.00001美元，注册股本总额仍为50,000美元，未见变动。已发行股份方面，由于有1,200,000股普通股通过期权行使获发行，截至3月末，公司已发行股份由上月底的672,361,350股增至673,561,350股，库存股数量维持在7,744,000股不变，合计总股本681,305,350股。购回与注销方面，公司于2025年分别购回的1,485,000股与1,000,000股普通股，截至2026年3月31日尚未注销。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624540176","title":"智通港股早知道 | 美国执行载人绕月任务火箭发射升空 国际能源署署长：4月石油供应缺口将达到3月的两倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2624540176","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624540176?lang=zh_cn&edition=full","pubTime":"2026-04-02 07:33","pubTimestamp":1775086385,"startTime":"0","endTime":"0","summary":"美国执行载人绕月任务火箭发射升空当地时间4月1日傍晚，美国航空航天局新一代登月火箭“太空发射系统”从佛罗里达州肯尼迪航天中心发射升空，执行“阿耳忒弥斯2号”载人绕月任务。这是美国自1972年以来首次载人飞向月球。据知情人士透露，这家卫星制造与火箭发射公司已以保密方式递交上市申请。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424319.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300759","02256","LU0880133367.SGD","BK4570","LU1152091754.HKD","02315","BK1593","BK1610","BK1194","06681","LU1960683339.HKD","BK1600","BK1141","BK1576","688796","00460","LU1993786604.SGD","300750","BK1116","BK4585","XLE","LU0067412154.USD","LU1008478684.HKD","BK1191","XOP","BK1161","03759","LU1807302812.USD","BK4588","BK1515","03750","01857","LU1152091168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624593383","title":"港股异动 | 和誉-B(02256)盘中涨近10% FGFR4抑制剂依帕戈替尼获EMA授予孤儿药资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2624593383","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624593383?lang=zh_cn&edition=full","pubTime":"2026-04-01 15:57","pubTimestamp":1775030256,"startTime":"0","endTime":"0","summary":"消息面上，和誉宣布，其自主研发的高选择性小分子FGFR4抑制剂依帕戈替尼已获得欧洲药品管理局授予的孤儿药资格，用于治疗肝细胞癌。目前，依帕戈替尼正在全球多地开展临床研究，此次获EMA授予ODD，将为该产品在欧洲的临床开发、注册申报与商业化进程提供有力支持。除本次获得EMA孤儿药资格外，依帕戈替尼此前还分别获得了美国食品药品监督管理局授予的ODD和快速通道资格认定，以及中国国家药品监督管理局授予的突破性疗法认定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU2476274720.SGD","IE00B543WZ88.USD","02256","BK4588","EMA","BK4081","LU2488822045.USD","LU2778985437.USD","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","VXUS","BK4585","LU2476274308.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112160524","title":"和誉-BFGFR4抑制剂依帕格雷替尼获EMA授予肝细胞癌孤儿药资格","url":"https://stock-news.laohu8.com/highlight/detail?id=1112160524","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112160524?lang=zh_cn&edition=full","pubTime":"2026-04-01 10:04","pubTimestamp":1775009054,"startTime":"0","endTime":"0","summary":"和誉生物制药宣布，其研发的FGFR4抑制剂依帕格雷替尼（Irpagratinib）已获得欧洲药品管理局（EMA）授予的孤儿药资格，用于治疗肝细胞癌。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2778985437.USD","LU2476274720.SGD","IE00BPRC5H50.USD","IE00B5MMRT66.SGD","LU2488822045.USD","IE00B543WZ88.USD","02256","LU2476274308.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199542666","title":"和誉-B旗下Irpagratinib获EMA授予肝细胞癌孤儿药资格","url":"https://stock-news.laohu8.com/highlight/detail?id=1199542666","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199542666?lang=zh_cn&edition=full","pubTime":"2026-03-31 20:32","pubTimestamp":1774960353,"startTime":"0","endTime":"0","summary":"和誉-B宣布，其研发的创新药物Irpagratinib已获得欧洲药品管理局授予的孤儿药资格认定，适应症为肝细胞癌。孤儿药资格是EMA为鼓励针对罕见疾病创新疗法研发而设立的特殊认定。获得该资格的药物将在欧洲市场享受一系列政策支持，包括临床开发指导、上市后市场独占期等权益。此次认定标志着Irpagratinib在肝细胞癌治疗领域的临床价值获得国际监管机构认可。此次EMA的认定将加速其在欧洲市场的开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B5MMRT66.SGD","LU2476274308.USD","BK1161","IE00B543WZ88.USD","LU2778985437.USD","02256","IE00BPRC5H50.USD","LU2488822045.USD","LU2476274720.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623581546","title":"和誉-B(02256)：FGFR4抑制剂依帕戈替尼获EMA授予孤儿药资格，用于治疗肝细胞癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2623581546","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623581546?lang=zh_cn&edition=full","pubTime":"2026-03-31 20:32","pubTimestamp":1774960347,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B 发布公告，公司附属公司上海和誉生物医药科技有限公司宣布，其自主研发的高选择性口服小分子FGFR4抑制剂依帕戈替尼已获得欧洲药品管理局授予的孤儿药资格，用于治疗肝细胞癌。目前，依帕戈替尼正在全球多地开展临床研究，此次获EMA授予ODD，将为该产品在欧洲的临床开发、注册申报与商业化进程提供有力支持。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423262.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU2476274308.USD","BK4081","02256","IE00BPRC5H50.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU2488822045.USD","LU2476274720.SGD","EMA","LU2778985437.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124008086","title":"和誉-BFgfr2/3抑制剂Absk061获FDA批准开展针对儿童软骨发育不全的新药临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1124008086","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124008086?lang=zh_cn&edition=full","pubTime":"2026-03-31 14:12","pubTimestamp":1774937535,"startTime":"0","endTime":"0","summary":"和誉-B（Abbisko Therapeutics）宣布，其研发的Fgfr2/3抑制剂Absk061已获得美国食品药品监督管理局（FDA）的新药临床试验（IND）批准，将用于治疗儿童软骨发育不全（Achondroplasia）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","IE00B5MMRT66.SGD","LU2476274720.SGD","02256","IE00BPRC5H50.USD","IE00B543WZ88.USD","LU2778985437.USD","BK1161","LU2476274308.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abbisko.com","stockEarnings":[{"period":"1week","weight":-0.0479},{"period":"1month","weight":0.0687},{"period":"3month","weight":0.0336},{"period":"6month","weight":-0.1126},{"period":"1year","weight":0.6845},{"period":"ytd","weight":-0.0069}],"compareEarnings":[{"period":"1week","weight":-0.0054},{"period":"1month","weight":0.0399},{"period":"3month","weight":-0.0588},{"period":"6month","weight":-0.005},{"period":"1year","weight":0.1653},{"period":"ytd","weight":0.0057}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和誉开曼有限责任公司是一家临床阶段生物制药公司。该公司致力于发现和开发创新差异化的小分子肿瘤疗法。该公司拥有两款核心候选产品ABSK011和 ABSK091，以及12款其他在研产品。ABSK011是一种强效且高选择性的成纤维细胞生长因子受体4(FGFR4) 小分子抑制剂。ABSK091 是一种分子靶向候选产品，也是 FGFR亚型 1、2和3的强效和选择性抑制剂。该公司的产品主要用于肝细胞癌(HCC)、尿路上皮癌(UC) 和胃癌(GC)。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.122249},{"month":2,"riseRate":0.8,"avgChangeRate":0.040621},{"month":3,"riseRate":0.4,"avgChangeRate":0.033777},{"month":4,"riseRate":0.4,"avgChangeRate":0.005698},{"month":5,"riseRate":0.25,"avgChangeRate":0.029375},{"month":6,"riseRate":0.5,"avgChangeRate":0.006841},{"month":7,"riseRate":0.75,"avgChangeRate":0.047273},{"month":8,"riseRate":0.5,"avgChangeRate":0.114048},{"month":9,"riseRate":0.75,"avgChangeRate":0.043844},{"month":10,"riseRate":0.5,"avgChangeRate":-0.043137},{"month":11,"riseRate":0.6,"avgChangeRate":0.159978},{"month":12,"riseRate":0,"avgChangeRate":-0.092694}],"exchange":"SEHK","name":"和誉-B","nameEN":"ABBISKO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和誉-B(02256)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和誉-B,02256,和誉-B股票,和誉-B股票老虎,和誉-B股票老虎国际,和誉-B行情,和誉-B股票行情,和誉-B股价,和誉-B股市,和誉-B股票价格,和誉-B股票交易,和誉-B股票购买,和誉-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和誉-B(02256)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}